调节新冠病毒肺炎患者肾素-血管紧张素和利钠肽系统的药物制剂 - Suppr

Suppr

超能文献

Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients.

作者信息

Vitiello Antonio, Ferrara Francesco

机构信息

Pharmaceutical Department, Usl Umbria 1, A. Migliorati street, 06132, Perugia, Italy.

出版信息

Wien Klin Wochenschr. 2021 Sep;133(17-18):983-988. doi: 10.1007/s00508-021-01855-6. Epub 2021 Apr 20.

DOI:10.1007/s00508-021-01855-6

PMID:33877436

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8055751/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a648/8055751/668df892868a/508_2021_1855_Fig1_HTML.jpg

相似文献

Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients.

Wien Klin Wochenschr. 2021 Sep;133(17-18):983-988. doi: 10.1007/s00508-021-01855-6. Epub 2021 Apr 20.

Renin-Angiotensin System Modulation in Adults With COVID-19.

JAMA. 2023 Aug 15;330(7):663-664. doi: 10.1001/jama.2023.10783.

Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis.

Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):335-337. doi: 10.1093/ehjcvp/pvaa074.

Renin-Angiotensin System Modulation in Adults With COVID-19-Reply.

JAMA. 2023 Aug 15;330(7):664-665. doi: 10.1001/jama.2023.10786.

Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.

High Blood Press Cardiovasc Prev. 2021 Mar;28(2):129-139. doi: 10.1007/s40292-021-00439-9. Epub 2021 Feb 26.

Dual blockade of the renin-angiotensin system with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).

Br J Clin Pharmacol. 2011 Mar;71(3):313-5. doi: 10.1111/j.1365-2125.2011.03918.x.

Angiotensin converting enzyme 2 at the interface between renin-angiotensin system inhibition and coronavirus disease 2019.

J Physiol. 2020 Oct;598(19):4181-4195. doi: 10.1113/JP280138. Epub 2020 Aug 13.

Angiotensin Receptor Blockers Are Not Just for Hypertension Anymore.

Physiology (Bethesda). 2021 May 1;36(3):160-173. doi: 10.1152/physiol.00036.2020.

Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?

Pharmacol Res. 2020 Sep;159:104959. doi: 10.1016/j.phrs.2020.104959. Epub 2020 Jun 4.

Drugs and the renin-angiotensin system in covid-19.

BMJ. 2020 Apr 2;369:m1313. doi: 10.1136/bmj.m1313.

引用本文的文献

Long COVID could become a widespread post-pandemic disease? A debate on the organs most affected.

Naunyn Schmiedebergs Arch Pharmacol. 2023 Jul;396(7):1583-1589. doi: 10.1007/s00210-023-02417-5. Epub 2023 Feb 11.

Effects of Vitamin D on the Renin-Angiotensin System and Acute Childhood Pneumonia.

Antibiotics (Basel). 2022 Nov 3;11(11):1545. doi: 10.3390/antibiotics11111545.

Current Insights and Molecular Docking Studies of the Drugs under Clinical Trial as RdRp Inhibitors in COVID-19 Treatment.

Curr Pharm Des. 2022;28(46):3677-3705. doi: 10.2174/1381612829666221107123841.

Pregnancy and COVID-19, focus on vaccine and pharmacological treatment.

J Reprod Immunol. 2022 Jun;151:103630. doi: 10.1016/j.jri.2022.103630. Epub 2022 Apr 21.

Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients.

Curr Res Pharmacol Drug Discov. 2021;2:100056. doi: 10.1016/j.crphar.2021.100056. Epub 2021 Sep 16.

Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment.

Egypt Heart J. 2021 Nov 18;73(1):103. doi: 10.1186/s43044-021-00228-8.

A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?

Immunol Res. 2022 Feb;70(1):129-133. doi: 10.1007/s12026-021-09244-x. Epub 2021 Nov 5.

COVID-19 vaccines and decreased transmission of SARS-CoV-2.

Inflammopharmacology. 2021 Oct;29(5):1357-1360. doi: 10.1007/s10787-021-00847-2. Epub 2021 Jul 19.

Plausible Positive Effects of Statins in COVID-19 Patient.

Cardiovasc Toxicol. 2021 Oct;21(10):781-789. doi: 10.1007/s12012-021-09674-x. Epub 2021 Jul 13.

The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections.

Naunyn Schmiedebergs Arch Pharmacol. 2021 Jul;394(7):1589-1593. doi: 10.1007/s00210-021-02108-z. Epub 2021 Jun 21.

本文引用的文献

Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade.

Hum Immunol. 2021 Apr;82(4):264-269. doi: 10.1016/j.humimm.2021.01.007. Epub 2021 Jan 20.

Drugs acting on the renin-angiotensin system and SARS-CoV-2.

Drug Discov Today. 2021 Apr;26(4):870-874. doi: 10.1016/j.drudis.2021.01.010. Epub 2021 Jan 21.

Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19.

Med Hypotheses. 2021 Feb;147:110486. doi: 10.1016/j.mehy.2021.110486. Epub 2021 Jan 7.

Efficacy of synthetic glucocorticoids in COVID-19 endothelites.

Naunyn Schmiedebergs Arch Pharmacol. 2021 May;394(5):1003-1007. doi: 10.1007/s00210-021-02049-7. Epub 2021 Jan 14.

Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?

Ir J Med Sci. 2021 Nov;190(4):1637-1638. doi: 10.1007/s11845-020-02482-2. Epub 2021 Jan 12.

Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times?

Indian J Pharmacol. 2020 Sep-Oct;52(5):441-442. doi: 10.4103/ijp.IJP_417_20.

Remdesivir versus ritonavir/lopinavir in COVID-19 patients.

Ir J Med Sci. 2021 Aug;190(3):1249-1250. doi: 10.1007/s11845-020-02440-y. Epub 2020 Nov 18.

Remdesivir and COVID-19.

Ir J Med Sci. 2021 Aug;190(3):1237-1238. doi: 10.1007/s11845-020-02401-5. Epub 2020 Oct 17.

Activation of angiotensin II type-2 receptor protects against cigarette smoke-induced COPD.

Pharmacol Res. 2020 Nov;161:105223. doi: 10.1016/j.phrs.2020.105223. Epub 2020 Oct 2.

Therapeutic Strategies for SARS-CoV-2 acting on ACE-2.

Eur J Pharm Sci. 2021 Jan 1;156:105579. doi: 10.1016/j.ejps.2020.105579. Epub 2020 Sep 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients.

Wien Klin Wochenschr. 2021 Sep;133(17-18):983-988. doi: 10.1007/s00508-021-01855-6. Epub 2021 Apr 20.

Renin-Angiotensin System Modulation in Adults With COVID-19.

JAMA. 2023 Aug 15;330(7):663-664. doi: 10.1001/jama.2023.10783.

Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis.

Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):335-337. doi: 10.1093/ehjcvp/pvaa074.

Renin-Angiotensin System Modulation in Adults With COVID-19-Reply.

JAMA. 2023 Aug 15;330(7):664-665. doi: 10.1001/jama.2023.10786.

Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.

High Blood Press Cardiovasc Prev. 2021 Mar;28(2):129-139. doi: 10.1007/s40292-021-00439-9. Epub 2021 Feb 26.

Dual blockade of the renin-angiotensin system with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).

Br J Clin Pharmacol. 2011 Mar;71(3):313-5. doi: 10.1111/j.1365-2125.2011.03918.x.

Angiotensin converting enzyme 2 at the interface between renin-angiotensin system inhibition and coronavirus disease 2019.

J Physiol. 2020 Oct;598(19):4181-4195. doi: 10.1113/JP280138. Epub 2020 Aug 13.

Angiotensin Receptor Blockers Are Not Just for Hypertension Anymore.

Physiology (Bethesda). 2021 May 1;36(3):160-173. doi: 10.1152/physiol.00036.2020.

Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?

Pharmacol Res. 2020 Sep;159:104959. doi: 10.1016/j.phrs.2020.104959. Epub 2020 Jun 4.

Drugs and the renin-angiotensin system in covid-19.

BMJ. 2020 Apr 2;369:m1313. doi: 10.1136/bmj.m1313.

引用本文的文献

Long COVID could become a widespread post-pandemic disease? A debate on the organs most affected.

Naunyn Schmiedebergs Arch Pharmacol. 2023 Jul;396(7):1583-1589. doi: 10.1007/s00210-023-02417-5. Epub 2023 Feb 11.

Effects of Vitamin D on the Renin-Angiotensin System and Acute Childhood Pneumonia.

Antibiotics (Basel). 2022 Nov 3;11(11):1545. doi: 10.3390/antibiotics11111545.

Current Insights and Molecular Docking Studies of the Drugs under Clinical Trial as RdRp Inhibitors in COVID-19 Treatment.

Curr Pharm Des. 2022;28(46):3677-3705. doi: 10.2174/1381612829666221107123841.

Pregnancy and COVID-19, focus on vaccine and pharmacological treatment.

J Reprod Immunol. 2022 Jun;151:103630. doi: 10.1016/j.jri.2022.103630. Epub 2022 Apr 21.

Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients.

Curr Res Pharmacol Drug Discov. 2021;2:100056. doi: 10.1016/j.crphar.2021.100056. Epub 2021 Sep 16.

Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment.

Egypt Heart J. 2021 Nov 18;73(1):103. doi: 10.1186/s43044-021-00228-8.

A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?

Immunol Res. 2022 Feb;70(1):129-133. doi: 10.1007/s12026-021-09244-x. Epub 2021 Nov 5.

COVID-19 vaccines and decreased transmission of SARS-CoV-2.

Inflammopharmacology. 2021 Oct;29(5):1357-1360. doi: 10.1007/s10787-021-00847-2. Epub 2021 Jul 19.

Plausible Positive Effects of Statins in COVID-19 Patient.

Cardiovasc Toxicol. 2021 Oct;21(10):781-789. doi: 10.1007/s12012-021-09674-x. Epub 2021 Jul 13.

The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections.

Naunyn Schmiedebergs Arch Pharmacol. 2021 Jul;394(7):1589-1593. doi: 10.1007/s00210-021-02108-z. Epub 2021 Jun 21.

本文引用的文献

Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade.

Hum Immunol. 2021 Apr;82(4):264-269. doi: 10.1016/j.humimm.2021.01.007. Epub 2021 Jan 20.

Drugs acting on the renin-angiotensin system and SARS-CoV-2.

Drug Discov Today. 2021 Apr;26(4):870-874. doi: 10.1016/j.drudis.2021.01.010. Epub 2021 Jan 21.

Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19.

Med Hypotheses. 2021 Feb;147:110486. doi: 10.1016/j.mehy.2021.110486. Epub 2021 Jan 7.

Efficacy of synthetic glucocorticoids in COVID-19 endothelites.

Naunyn Schmiedebergs Arch Pharmacol. 2021 May;394(5):1003-1007. doi: 10.1007/s00210-021-02049-7. Epub 2021 Jan 14.

Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?

Ir J Med Sci. 2021 Nov;190(4):1637-1638. doi: 10.1007/s11845-020-02482-2. Epub 2021 Jan 12.

Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times?

Indian J Pharmacol. 2020 Sep-Oct;52(5):441-442. doi: 10.4103/ijp.IJP_417_20.

Remdesivir versus ritonavir/lopinavir in COVID-19 patients.

Ir J Med Sci. 2021 Aug;190(3):1249-1250. doi: 10.1007/s11845-020-02440-y. Epub 2020 Nov 18.

Remdesivir and COVID-19.

Ir J Med Sci. 2021 Aug;190(3):1237-1238. doi: 10.1007/s11845-020-02401-5. Epub 2020 Oct 17.

Activation of angiotensin II type-2 receptor protects against cigarette smoke-induced COPD.

Pharmacol Res. 2020 Nov;161:105223. doi: 10.1016/j.phrs.2020.105223. Epub 2020 Oct 2.

Therapeutic Strategies for SARS-CoV-2 acting on ACE-2.

Eur J Pharm Sci. 2021 Jan 1;156:105579. doi: 10.1016/j.ejps.2020.105579. Epub 2020 Sep 30.